Epidemiology, clinical profiles, and prognostic value of COVID‐19‐related cutaneous manifestations in African populations: a rapid narrative review

Abstract

BackgroundSkin manifestations’ true prognostic value, and clinical and epidemiological pictures in SARS‐CoV‐2 infection in African populations are poorly described and understudied. More familiarity with COVID‐19 cutaneous manifestations may aid in early clinical diagnosis or guide prognosis.MethodsIn this literature review, we looked for potential studies published from December 2019 to March 2023 on COVID‐19 cutaneous lesions in African populations. Our key questions were focused on the prognostic values of cutaneous manifestations related to COVID‐19.ResultsOur findings show that cutaneous manifestations of COVID‐19 vary by country and severity of COVID‐19, primarily multisystem inflammatory syndrome (MIS). Significant differences were also found between various dermatological lesions, primarily MIS, erythema multiforme‐like, livedoid, vesicular, or varicella‐like rashes, urticarial, maculopapular or morbilliform rashes, and chilblain‐like or pernio‐like rashes. There were 47.5% (115/242) of MIS cases reported in nine published African studies. Our findings also revealed that MIS may be diagnosed in 2–7 days due to early onset rash. Advanced age, obesity, diabetes, cardiovascular disease, HIV, tuberculosis, asthma, atopic disease, underweight, malnutrition, and malignancy were found to be associated with COVID‐19 cutaneous manifestations in African populations.ConclusionsCOVID‐19‐related skin manifestations in African populations are important as a driving force in COVID‐19 prognosis.